A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

NCT03266783 ·Status: COMPLETED ·Phase: PHASE4

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study

NCT02559856 ·Status: COMPLETED ·Phase: PHASE4

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

NCT00680186 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

NCT00643201 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

NCT00633893 ·Status: COMPLETED ·Phase: PHASE3

Secondary Prevention of Venous Thrombo Embolism (VTE).

NCT00329238 ·Status: COMPLETED ·Phase: PHASE3

Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin

NCT05819125 ·Status: TERMINATED

Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome

NCT02295475 ·Status: COMPLETED ·Phase: PHASE4

Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

NCT00252005 ·Status: COMPLETED ·Phase: PHASE2

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

NCT04168203 ·Status: COMPLETED ·Phase: PHASE4

Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data

NCT04818151 ·Status: COMPLETED

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

NCT00457002 ·Status: COMPLETED ·Phase: PHASE3

The DARE Warfarin CER Study

NCT03271450 ·Status: UNKNOWN

Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra

NCT02270918 ·Status: COMPLETED ·Phase: PHASE1

3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE

NCT00365950 ·Status: COMPLETED ·Phase: PHASE4

A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) Treatment

NCT03812835 ·Status: WITHDRAWN

Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study

NCT02450682 ·Status: WITHDRAWN ·Phase: PHASE2

Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism

NCT00788736 ·Status: COMPLETED

Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden

NCT02492828 ·Status: COMPLETED

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

NCT02585713 ·Status: COMPLETED ·Phase: PHASE3

AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients

NCT01780987 ·Status: COMPLETED ·Phase: PHASE3

A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer

NCT05643885 ·Status: COMPLETED

A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark

NCT02591732 ·Status: COMPLETED

Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis

NCT00005684 ·Status: COMPLETED

Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

NCT06232551 ·Status: RECRUITING ·Phase: NA